Dr Sarah Heynemann

⭐️ NEW PUBLICATION⭐️In 2024 @iaslc's JTO published a debate on the role of #equipoise in Ph3 RCTs of precision oncology therapeutics in #NSCLC. (See prior 🧵x.com/CancerEthicsDo…) In a new letter we highlight key implications if equipoise is uncertain in a given RCT...

Looking fwd to inaugural @MOGA_ORG ethics webinar Wed 19/3- on COIs in oncology, with stellar line-up including: Prof @WendyLipworth Dr Lisa Parker Prof @jrzalcberg & Prof Michael Millward.

COIs what are they? when could they be a problem? how might we manage them?

Link below:

Realities of the modern EBM/perception of “evidence”/access to drugs conversation #AABHL24 @AABHL @SydHealthEthics

Some thoughts to ponder as #AABHL24 kicks off by @IABioethics president Caesar Atuire re the challenges for bioethics to ponder in the modern era @AABHL @SydHealthEthics

⭐️ New Paper⭐️ Equipoise + modern cancer RCTs, using thoracic oncology as an exemplar - whose uncertainty matters (most)? 💥 A debate💥

jto.org/article/S1556-… with @WendyLipworth McLachlan @JenAMPhilip @TommyJohn00 Kerridge @SydHealthEthics

In this paper, we outline- a 🧵